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APOE ε4 moderates abnormal CSF-abeta-42
levels, while neurocognitive impairment is
associated with abnormal CSF tau levels in HIV+
individuals – a cross-sectional observational study
Lucette A Cysique1,2,3,4*, Timothy Hewitt4,5, Juliana Croitoru-Lamoury1,4, Kevin Taddei6,7, Ralph N Martins6,7,8,
Constance SN Chew9, Nicholas NWS Davies10, Patricia Price9 and Bruce J Brew1,3,4
Abstract
Background: Cerebrospinal fluid (CSF) biomarkers Aβ1-42, t-tau and p-tau have a characteristic pattern in Alzheimer’s
Disease (AD). Their roles in HIV-associated neurocognitive disorder (HAND) remains unclear.
Methods: Adults with chronic treated HIV disease were recruited (n = 43, aged 56.7 ± 7.9; 32% aged 60+; median HIV
duration 20 years, >95% plasma and CSF HIV RNA <50 cp/mL, on cART for a median 24 months). All underwent
standard neuropsychological testing (61% had HAND), APOE genotyping (30.9% carried APOE ε4 and 7.1% were
ε4 homozygotes) and a lumbar puncture. Concentrations of Aβ1-42, t-tau and p-tau were assessed in the CSF
using commercial ELISAs. Current neurocognitive status was defined using the continuous Global Deficit Score,
which grades impairment in clinically relevant categories. History of HAND was recorded. Univariate correlations
informed multivariate models, which were corrected for nadir CD4-T cell counts and HIV duration.
Results: Carriage of APOE ε4 predicted markedly lower levels of CSF Aβ1-42 in univariate (r = -.50; p = .001) and
multivariate analyses (R2 = .25; p < .0003). Greater levels of neurocognitive impairment were associated with higher CSF
levels of p-tau in univariate analyses (r = .32; p = .03) and multivariate analyses (R2 = .10; p = .03). AD risk prediction
cut-offs incorporating all three CSF biomarkers suggested that 12.5% of participants had a high risk for AD. Having a
CSF-AD like profile was more frequent in those with current (p = .05) and past HIV-associated dementia (p = .03).
Conclusions: Similarly to larger studies, APOE ε4 genotype was not directly associated with HAND, but moderated CSF
levels of Aβ1-42 in a minority of participants. In the majority of participants, increased CSF p-tau levels were associated
with current neurocognitive impairment. Combined CSF biomarker risk for AD in the current HIV+ sample is more than
10 times greater than in the Australian population of the same age. Larger prospective studies are warranted.
Keywords: HIV/AIDS, CSF, APOE, Aβ1-42, t-tau, p-tau, HIV-associated neurocognitive disorders
Background
The cerebrospinal fluid (CSF) biomarkers Aβ1-42, t-tau
and p-tau have a characteristic pattern in Alzheimer’s
Disease (AD) (AD profile: low levels of Aβ1-42 and high
levels of t-and p-tau [1,2]) and may be associated with the
cognitive changes seen in people with HIV-associated
neurocognitive disorder (HAND). Links between AD and
HAND are becoming increasingly relevant as AD is gener-
ally associated with age, and HIV+ individuals now live
longer on effective combined antiretroviral therapy
(cART). Also, there is some preliminary evidence for
accelerated aging of the brain in middle-aged HIV+ indi-
viduals [3]. Three studies have investigated a potential link
between these two disease entities. Brew and colleagues
found an AD-like pattern of CSF Aβ1-42, t-tau and p-tau
concentrations in mild to moderate HAND (N = 87; 46
AIDS-dementia complex (ADC) stage 1; 41 ADC stage 2;
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age: μ = 42; SD = 11) consistent with that seen in AD [4].
A study in HIV+ individuals with HAND (N = 21; 3 ADC
stage 1; 18 ADC stages 2-4; age: μ = 38; SD = 18;) reported
low levels of Aβ1-42 but normal levels of t-tau and p-tau
[5]. Another study (N = 49; 30 MCD; 11 HAD; 8 un-
known; age: μ = 48; SD = 8) reported low levels of Aβ1-42
and t-tau and p-tau [6]. These inconsistent results may re-
flect heterogeneity in the severity of HAND, the efficacy
of cART, HIV disease duration and/or patient age.
Importantly, no study included APOE (Apolipoprotein E)
genotyping, which may affect AD independently, or in
association with, CSF biomarkers depending on the age
of the subject [7]. The ε4 allele of APOE, an apolipo-
protein thought to be partially responsible for amyloid
clearance in the CNS, is one of the greatest known risk
factors for late-onset sporadic AD [8,9]. Large cohort
studies have provided conflicting results regarding the role
of APOE in HIV+ persons with HAND. A study based on
the Hawaii Aging with HIV Cohort [10] (N = 182) associ-
ated APOE ε4 carriage with HAND, but only in older
participants. The largest study conducted in an ethnic-
ally diverse cohort [11] (Wilford Hall Medical Center,
WHMC; 1,267 HIV-seropositive adults and 1,132 ethnic-
ally similar HIV-seronegative controls) found an associ-
ation between APOE ε4/ε4 genotype and acceleration of
HIV disease, but not with HAD. However the authors only
assessed HAD rather than the complete HAND spectrum.
Moreover, it is not clear how HAD was defined and
assessed. More recently the CNS HIV Antiretroviral Ther-
apy Effects Research (CHARTER) study [12] of 466 HIV+
participants (mean age = 44) who received a comprehen-
sive HAND assessment showed no association between
APOE ε4 carriage and HAND. They similarly found no
association when they restricted their analyses to those
with moderate HAND (Mild Neurocognitive Disorder
(MND) and HAD). Age did not influence their results,
but their sample included only 3.7% of persons aged 60+,
compared to 25% in the Hawaii Aging with HIV Cohort
[10]. The authors conclude that within the age-group
they investigated APOE was not associated with HAND,
confirming other smaller studies in same-age or younger
samples [13-15], but stated that their results does not
“preclude emergence of an association between APOE
status and HAND as this population ages”, so further
studies are needed.
The current study included 43 chronic HIV+ adults
aged 56.7 ± 7.9 (32% aged 60+) years on long-term
cART with no detectable HIV RNA in their plasma or
CSF. The aims were: 1. Investigate whether the bio-
markers Aβ1-42, t-tau and p-tau follow a similar pat-
tern to that found in AD and assess the prevalence of
CSF-AD like profile. 2. Investigate the relationship be-
tween APOE genotype, CSF biomarker levels and sever-
ity of HAND in these individuals. We hypothesized that
HIV+ adults with HAND would be more likely to have
a CSF AD-like profile than those who did not have
HAND. Our second aim was exploratory, as APOE
genotypes have not ben correlated CSF markers in chronic
HIV infection.
Methods
Study participants
Participants were recruited through the HIV and Neurology
Clinics at St Vincent’s Hospital, Sydney, Australia. Eligibility
criteria included: age ≥45 years, stable cART ≥6 months,
nadir CD4 T-cells ≤350/ul and HIV duration ≥5 years.
Exclusion criteria included a history of non-HIV related
neurological disorders or uncontrolled axis I psychiatric
disorders, history of psychotic disorder, substance/alco-
hol use disorders (DSM-IV) within 12 months of enrol-
ment, history of loss of consciousness >30 minutes, and
non-proficiency in English (published protocol details
[3,16]). St. Vincent’s Hospital, The University of New
South Wales, and the University of Western Australia
Human Research Ethics Committees approved protocols.
All participants provided written informed consent.
Current impairment status
Detailed testing procedures have been published Lane et al.
[16] and Cysique et al. [17]. Briefly, HIV+ participants
underwent a standard neuropsychological evaluation
assessing seven cognitive domains. Impairment status was
determined using local normative standards (z-scores) de-
veloped in a demographically comparable HIV- sample
recruited as part of the HIV and Brain Aging research
program at the University of New South Wales (PI,
LAC). Details on methods and the sample characteristics
used to develop local norms have been published [17].
The standard Global Deficit Score (GDS) method [18,19]
was used to classify impairment. As per convention [18,19],
GDS ≥ 0.5 was used to define a clinically relevant level of
impairment yielding a discrete outcome (impaired or unim-
paired) or a continuous outcome. A higher GDS indicates
greater impairment. The standard GDS cut-off of ≥0.5 is
widely used to assess HIV-related brain injury and meets
the Frascatti criteria for HAND [20]. For each participant,
we determined the HAND classification (Asymptomatic
Neurocognitive Impairment: ANI; Mild Neurocognitive
disorder: MND; or HAD) as follows: [20]. GDS ≥ 0.5 & no
Independence in Activities of Daily Living (IADL) [21] de-
cline = ANI; GDS ≥ 0.5 & mild/moderate IADL decline =
MND; GDS ≥ 1.5 & severe IADL decline = HAD. IADL
information was obtained from a standard IADL scale, the
Patients Assessment of Own Functioning Inventory [22]
and any clinical evidence of IADL decline (medical record;
nurse information).
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Past HAND status
History of HAND was based on standard neurological
and neuropsychological examinations, MRI/MRS scans
and an extended panel of plasma and CSF biomarkers,
as described previously [23]. LC consulted the medical
records and recorded HAND diagnoses reported using
the AIDS Dementia Complex nomenclature [24]. This
was adapted to the HAND 2007 criteria [25] by LC (see
Additional file 1) and reviewed by BJB (HIV Neurologist)
to reach clinically relevant diagnoses of MND and HAD
[25]. Past HAND status was also analysed as a dichomotous
variable.
Specimen collection and quantitation of biomarkers in
cerebrospinal fluid
CSF was stored at -70°C until assayed. CSF Aβ1-42 concen-
trations were determined using a sandwich enzyme-linked
immunoassay (ELISA) with a limit of detection of 15 pg/
mL (Innotest™ β-amyloid(1-42) ELISA, INNOGENETICS N.
V, Ghent, Belgium). CSF t-tau and p-tau concentrations
were determined using a sandwich ELISA with limits
of detection of 87 and 15 pg/mL (Innotest™ hTAU Anti-
gen assay and Innotest™ PHOSPHO-TAU(181P) ELISA,
INNOGENETICS N.V). As within-laboratory variation
has been reported [26], we tested our procedure in a eight
HIV- controls, comprising three cognitively healthy adults
and five adults with AD recruited from the Memory
Clinics of the Sir James McCusker Alzheimer’s Disease
Research Unit (Western Australia) and the Neurology AD
clinics at St. Vincent’s Hospital. AD diagnoses were based
on the NINCS-ADRA [27] and DSM-IV [28] criteria. CSF
samples were examined blind to the AD & HIV status and
vice versa. CSF markers concentrations are presented in
Figure 1. Laboratory analyses were reliable across dupli-
cates (p < .0001). To examine the sensitivity and specificity
of our assay procedure, we used published cut-offs [29]
which display sensitivity (95%) and specificity (≥81%)
for AD and incipient AD [30]: CSF-AD profiles were 1).
t-tau >350 & Aβ1-42 < 530 pg/ml; 2). p-tau >60 & Aβ1-
42 < 530 pg/ml; 3). t-tau >350 pg/ml & Aβ1-42/p-tau <6.5.
Figure 1 Raw duplicate and average data for the CSF biomarkers. To assess the reliability of all the CSF biomarker concentrations, we performed
correlations between assays duplicate for t-tau, p-tau (r = .99; p < .0001) and Aβ1-42 (r = .95; p < .0001). They were highly reliable. To assess the within
group duplicate reliability we conducted a t-test between duplicate 1 and 2 within HIV, AD and HIV- group and all results were non-significant differences
(t-tau; p-tau: p > .90; Aβ1-42 p > .50).
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At least one CSF-AD profile was found in all AD patients
and none in the HIV- controls (see Figure 2). CSF Aβ1-42
was missing in three cases because there was insufficient
CSF, so cut-offss were based on 40 cases.
APOE genotyping
DNA was extracted from saliva or blood leukocytes using
QIAamp DNA mini Kits (QIAGEN; Valencia, CA) and
stored at -80°C. Two SNPs in the APOE gene (rs429358,
rs7412) defining the APOE ɛ3, ɛ4 and ɛ2 variants were
genotyped using TaqMan assays according to manufacturer’s
instructions. Median (range) genotyping success rates
were 99% (98%–100%).
Data analyses
Categorical data were assessed with the Fisher’s Exact Test.
Concentrations of t-tau, p-tau were log10 transformed to
approximate normal distributions. Univariate analyses
(Pearson and/or point biserial correlations) evaluated
associations between the CSF biomarkers and AD risk
factors [31] (APOE genotypes: homozygotes (ε4/ε4) vs. het-
erozygotes (ε4/ε2 or ε4/ε3) vs no ε4, and age), HIV-related
parameters [32] (nadir CD4 T-cell count and HIV duration
in years) and neurocognition (current GDS and past
HAND status).
Multivariate analyses comprised stepwise regression
models with CSF p-tau (t-tau was excluded as it corre-
lated with p-tau) and Aβ1-42 separately as outcomes.
For the Aβ1-42, predictors were included in the order
defined above. For p-tau, the continuous GDS was en-
tered first (based on univariate analyses), followed by
past HAND status, age, HIV disease markers and APOE
status. The model was re-run removing a priori APOE
and past HAND status. We used a forward model selec-
tion with the Akaike Information Criterion corrected
(AICc), as it is less reliant on p-value than other type of
stepwise selection methods. The model with the lowest
AICc yields the best compromise between goodness to
fit and model complexity [33]. Statistical analyses were
conducted using JMP 10 (SAS Inc).
Results
Demographic and clinical characteristics of the HIV+
group are presented in Table 1, whilst characteristics of
the reference samples are presented in Additional file 2.
HIV+ participants were characterized by historic im-
mune compromise, which had improved substantially on
cART. Only 2 cases had detectable HIV RNA in plasma
and one other in the CSF. These are considered to be “de-
tection blips” as participants were clinically stable on cART
and negative HIV RNA assessments had been recorded
within the previous 12 months (data not shown). Most
participants were well-educated white men. The AD
and control sample were older than the HIV+ sample
by design, but comparable for other demographics. They
were included to demonstrate reliability of CSF assays
and CSF-AD like profiling.
When the cut-offs distinguishing AD in HIV- and AD
cases (described in methods) were applied, 5% (2/40)
HIV+ participants had profile 1, 7.5% (3/40) had profile
2 and 7.5% (3/40) had profile 3. One participant met the
AD-CSF profile on all 3 cut-offs. In total, 12.5% (5/40)
had at least one CSF-AD like profile (Figure 2).
A diagnosis of HAND (versus GDS ≥0.5) did not asso-
ciate with having a CSF AD- like profile (12.5% with or
without HAND). However, those with HAD (40%) were
more likely to have a CSF AD-like profile than those
with ANI (0%; p = .05). They were also marginally more
likely to have a CSD AD-like profile compared to with
MND (16.7%), but this was not statistically significant.
Figure 2 Prevalence of clinically relevant CSF profiles. CSF Aβ1-42 was missing for three cases because of insufficient CSF sample; therefore
the CSF-AD like profiles were computed from 40 cases.
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Participants with past HAND status were more likely to
have at least one CSF AD-like profile than those with no
past HAND (31% versus 3.7%; p = .03). Among those with
past HAND, CSF AD-like profiles were marginally more
common in HAD (37.5%) than in MND (20%) but this
was not significant as there were only 8 HAD cases, 5
MND cases and 5 individuals with a CSF AD-like profile.
In univariate analyses (Table 2) APOE genotypes incorp-
orating ε4 associated with lower levels of CSF Aβ1-42
(p=.001). Moreover the current level of neurocognitive
impairment was associated with higher log10 levels of
p-tau (p = .03) and t-tau (p = .05).
In the multivariate model with CSF Aβ1-42 as the out-
come, APOE ε4 (R2 = .25; p = .0003) and age (R2 = .07;
p = .06) were optimal predictors based on the AICc cri-
terion (model R2 = .32; AICc = 536). The APOE effect
was driven by ε4/ε4 cases and one ε3/ε4 (Figure 3 repre-
sents the univariate correlation for clarity). The unusual
positive and weak effect of age on CSF Aβ1-42 suggests
a survivor bias in our cohort. This effect represents a
non-significant small correlation in univariate analyses
(see Table 2), but impacted the multivariate model.
In the first multivariate model with CSF log10 p-tau as the
outcome, and using all relevant study predictors, the AICc
selected the GDS (p = .13) as the optimal predictor and the
overall model was weak (model R2 = .05; AICc = 12) as cor-
relations between predictors affected the direct ex-
planatory power of the GDS. For example; the GDS was
associated with past HAND (p = .0008) so the increase in
p-tau reflects both current and past HAND (see Additional
file 3). In the second run of the model, APOE and past
HAND were excluded a priori, the GDS (p = .03) was se-
lected by the AICc. However the overall model was only
slightly improved, so the combination of factors still have
a relatively weak explanatory power (model R2 = .10;
AICc = 11.5). To highlight the effect of the GDS, we
present the univariate correlation in Figure 4.
Table 1 Clinical and laboratory characteristics in the entire
HIV+ group
HIV+ group only
Median Nadir CD4-T+ cells/μL 198 IQR: 31-279
Median current CD4-T+ cells/μL 597 IQR: 342-748
% Plasma undetectable HIV RNA
(<50 cp/mL)1
95.5% -
% CSF Undetectable HIV RNA
(<50 cp/mL)2
97.6% -
Median HIV duration (years) 20.5 IQR: 14-25
% AIDS status (CDC 1993) 70.5% -
% With past AIDS defining illness 53% -
Median current cART duration
(months)
30 IQR: 12-54
% MSM as HIV risk factor 89% -
Average educational level (years) 13.82 SD: 2.95
% Current hAND 61.3% -
% Past hAND 31.8% -
% APOE any ε4 allele carriers 30.9% (N = 13) -
% APOE ε4/ε4 allele carriers 7.1% (N = 3) -
% APOE ε2/ε3 allele carriers 7.1% (N = 3) -
% APOE ε3/ε3 allele carriers 61.9% (N = 26) -
IQR: Inter-quartile range.
SD: standard deviation.
MSM: Men who have sex with men.
HAND: HIV-associated neurocognitive disorders (Frascatti 2007 diagnostic criteria).
1. Two cases had detectable plasma viral load, which were considered blips,
as these cases were undetectable before and after the HIV RNA testing
concomitant to the current study neuropsychological testing. Not that those
cases were undetectable in the CSF.
2. One case had detectable CSF HIV RNA and this was also considered a blip
for the same reasons as for plasma HIV RNA. This case was undetectable in
the plasma.
Table 2 Correlations between individual CSF biomarkers,
AD risk markers, HIV/HAND risk markers, current overall
neurocognitive impairment and past HAND
Correlations between r p
APOE Log10 CSF t-tau −0.09 0.59
Age 0.16 0.31
Nadir CD4 −0.19 0.22
HIV duration 0.04 0.78
Past HAND 0.10 0.50
GDS (current) 0.29 0.05
APOE Log10 CSF p-tau −0.11 0.47
Age 0.08 0.61
Nadir CD4 −0.18 0.26
HIV duration −0.05 0.73
Past HAND 0.15 0.33
GDS (current) 0.32 0.03
APOE CSF Aβ1-42 −0.50 0.001
Age 0.16 0.31
Nadir CD4 −0.09 0.58
HIV duration −0.11 0.51
Past HAND −0.06 0.70
GDS (current) 0.18 0.26
Log10 CSF p-tau Log10 CSF t-tau 0.96 <.0001
CSF Aβ1-42 Log10 CSF t-tau 0.48 0.002
CSF Aβ1-42 Log10CSF p-tau 0.53 0.0004
APOE Genotypes were coded as follows: no ε4 = 1; heterozygotes ε4/ε2 or ε4/
ε3 = 2; genotypes: homozygotes ε4/ε4 = 3. Note that the correlation for APOE
is driven by the ε4/ε4 cases and one ε4/ε3 case.
We used Pearson and point-biserial correlations as appropriate.
The Global Deficit Score (GDS) is a summary score that is an average of all
the deficit scores across the test battery, and it grades normal vs. impaired
performance between 0-5. A higher GDS indicated greater current
overall impairment.
Past HAND: History of HAND yes was coded 1; no was coded 0.
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Discussion
The study is the first to associate CSF AD-like profiles with
current HAD, past MND and past HAD. While the num-
ber of cases with a CSF AD-like profile is small, this may be
explained by poor survival over the years before cART was
optimal. Despite this, it appears that HAD is either a risk
for low CSF AD-like profile or the reverse – which
would predict increases in HAD as the HIV+ population
ages. Because our study is cross-sectional, it is unclear
how HIV-related brain injury may have affected levels
of CSF biomarkers, though this would be consistent
with the impact of past HAND.
This study is the first to include both measurements of
CSF neurodegenerative markers and APOE profiling in
stable optimally treated HIV+ individuals. A novel finding
was that APOE ε4 moderated CSF Aβ1-42 levels. In
subjects without HIV, APOE ε4 carriage is associated
with lower CSF Aβ1-42 concentrations [34]. This correl-
ation emerges in subjects aged 46-65 years (the average
age of our cohort) and is clearer in those aged 66-89 years.
Similarly, HIV- homozygous carriers of the APOEε4 allele
have lower CSF Aβ1-42 levels than heterozygote carriers
[34]. Although our sample had a low APOE ε4/ε4
prevalence [cf: median 11.6%; range (4.9%–18.3)% in
the Australian population:] [35], the effect was robust and
maintained in multivariate analyses. As APOE genotype is
a significant risk factor for AD [7] and affects post-
mortem beta-amyloid burden in HAND [36], longitudinal
studies are warranted.
Our other main finding was that neurocognitive impair-
ment was associated with higher CSF p-tau and t-tau levels.
This is not seen in normal aging. For example cogni-
tively healthy individuals do not have elevated levels of
p-tau and t-tau, but ~19% show abnormal CSF Aβ1-42
concentrations [34,37]. This could mean that p-tau and
t-tau mark a greater risk for current HAND in middle-aged
HIV+ individuals [38].
Lastly, past immune compromise and longer HIV
duration may increase AD risk, as both are risk factors
for HAND [39]. This was not evident here as the n
value was low.
Our findings yield useful information for longitudinal
study addressing neurodegeneration in stably treated HIV
infection, and to in persons aged over 50-60 years. APOE
genotyping and CSF biomarkers should be investigated as
individual continuous outcomes as well as AD-like cut
offs. This strategy will help determine the clinical
relevance of a CSF neurodegenerative marker panel.
The inclusion of older participants at this stage of the
HIV epidemic has some caveats as most are survivors of
the pre-cART era. Thus our data may contain some sur-
vivor bias. Therefore until cohorts with no survivor bias
(i.e.,: individuals started on cART) are available, the neu-
roHIV community should remain cautious of a lack of
detection or weak signal of accelerated neurodegenera-
tion in aging HIV+ persons. Such cohorts will display a
lower prevalence of HAD but MND is still relatively com-
mon in persons on cART [17,20] and ANI can predict
neurocognitive deterioration [40].
Figure 3 Correlation between APOE status and CSF Aβ1-42.
Note that APOE genotyping is presented in Table 1.
Figure 4 Correlation between CSF p-tau, t-tau and neurocognitive
impairment (continuous GDS). A higher GDS indicates greater
neurocognitive impairment. t-tau and p-tau were log10 transformed.
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In addition CSF biomarkers and APOE genotype, other
mechanisms might explain β-amyloid dysregulation in
chronic HIV infection. Indeed our data suggests that
higher CSF Aβ1-42 concentrations may correlate with
CSF p-tau and t-tau levels. This is counter-intuitive as
lower CSF Aβ1-42 and increased tau mark AD. However
the inverse relationship was only seen in a sub-set of par-
ticipants. In others CSF Aβ1-42 concentrations are normal
or slightly elevated (Figure 1). Elevation of CSF Aβ1-42
concentrations may represent an anti-inflammatory effect
[41]. Supporting this interpretation is the fact that CSF
neopterin correlated with CSF Aβ1-42 (r = .40; p = .009).
Conclusions
At first glance, our results seem contrary to studies which
found no evidence of amyloid burden in HIV+ individuals
[42] or no relationship between HAND and APOE ε4
genotype [12]. However we show that APOE ε4 genotype
moderates the expression of CSF Aβ1-42 in participants
with HAND. Moreover as in larger studies [29], we find
that APOE does not directly impact HAND. Perhaps as
most individuals are still relatively young (<60 years),
amyloid build up is incomplete and tau pathologies may
be a more common trigger for brain damage. With evi-
dence that the CSF biomarker risk for AD in the current
HIV+ sample is over 10 times greater (12.5%) than in the
Australian population of the same age [43], this shows the
need for a longitudinal study of the aging HIV+ population.
Limitations
Our study offers new insights into the CSF biomarker
pathologies in HIV infection, but the design is cross-
sectional so the clinical consequences are unclear. Our
study included a medium size sample, but the participants
were well characterized and uniform in having achieved
viral suppression on cART. This excludes HIV replication
as a cause of HAND compared to previous studies [4-6].
Some APOE ε4 homozygotes may have died before cART
was available (i.e., survival bias), as the prevalence of
APOE ε4/ε4 is lower than in the Australian general
population.
Additional files
Additional file 1: Correspondence between the 1988 ADC and the
2007 American Academy of Neurology HAND diagnosAc nomenclature.
Additional file 2: Table S1. Study groups’ demographic characteristics.
Additional file 3: Table S2. Correlations between multivariate analyses
predictors.
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